Newbury Pharmaceuticals

Newbury Pharmaceuticals is pleased to announce the successful Marketing Authorization (MA) of Tofacitinib Newbury 5 mg and 10 mg film-coated tablets in Sweden as the first country in a Scandinavian re

Newbury Pharmaceuticals is pleased to announce the successful Marketing Authorization (MA) of Dalbavancin Newbury 500 mg powder for concentrate for solution for infusion in Sweden. No further country

STOCKHOLM (Nyhetsbyrån Direkt) Newbury Pharmaceuticals redovisar intäkter på 8,9 miljoner kronor (6,7) och ebitda-resultat på -4,0 miljoner kronor (-5,7) för det tredje kvartalet, mars-maj, i det brut

Quarter 3, March 2026 – May 2026Net revenue was 8 933 (6 686) tkr. EBITDA was -3 964 (-5 691) tkr. Operating cash flow was -10 286 (-5 787) tkr. Interim period, September 2025 – May 2026Net revenue wa

Redeyes analytiker Kevin Sule intervjuar Newbury Pharmaceuticals VD och grundare, Karl Karlsson, om bolagets nuvarande status, senaste delårsrapport och vägen mot lönsamhet.

Newbury Pharmaceuticals is pleased to announce the successful Marketing Authorization (MA) of Palbociclib Newbury tablets in Denmark as the first country in a Scandinavian registration procedure. Appr

The extraordinary general meeting of Newbury Pharmaceuticals AB took place on 15 April 2026. All decisions made by the general meeting are in accordance with the proposals presented in the notice. App

STOCKHOLM (Nyhetsbyrån Direkt) Newbury Pharmaceuticals redovisar intäkter på 8,5 miljoner kronor (12,4) och ebitda-resultat på -4,1 miljoner kronor (-1,0) för det andra kvartalet, december-februari, i

Quarter 2, December 2025 – February 2026Net revenue was 8 454 (12 434) tkr. EBITDA was -4 144 (-973) tkr. Operating cash flow was 2 260 (-6 371) tkr. Interim period, September 2025 – February 2026Net

Notice of Extraordinary General Meeting of Newbury Pharmaceuticals AB Tid: 15 april 2026 klockan 10.00.Plats: Medicon Village, Scheeletorget 1, Lund.Time: 15 April 2026 at 10:00 am.Place: Medicon Vill

Newbury Pharmaceuticals AB has agreed to extend and increase the existing loan agreement with AB Slädens Pensionsstiftelse nr 3, securing SEK 30 million in total financing through to 30 June 2027, and

Newbury Pharmaceuticals presenterade vid Stockholm Corporate Finance 17:e kapitalmarknadsdagar Life Science 2026.Läs fullständig analys

Newbury has signed a contract with a new partner to register and launch Prucalopride in Sweden. Prucalopride, 1 and 2 mg tablets, is a selective, high affinity 5-HT4 receptor agonist which targets the

Newbury Pharmaceuticals is pleased to announce that it has been awarded a 12-month tender for Pazopanib Newbury with the Danish procurement body Amgros, commencing on June 1, 2026. Pazopanib Newbury i

STOCKHOLM (Nyhetsbyrån Direkt) Newbury Pharmaceuticals hade intäkter på 11,7 miljoner kronor (6,5) och ett ebitda-resultat på -5,5 miljoner kronor (-3,8) under det första kvartalet, september-november

Quarter 1, September 2025 – November 2025Net revenue was 11 720 (6 538) tkr. EBITDA was -5 524 (-3 759) tkr. Operating cash flow was -6 549 (4 792) tkr. Cash position in the end of period was 7 919 (1